Kite, A Gilead Company

This study is testing two experimental treatments, KITE-363 and KITE-753, for people with B-cell lymphoma that has returned or stopped responding to standard therapy. These are personalized cell therapies made from a patient's own immune cells, engineered to attack two targets (C…

This study offers a special type of cell therapy called brexucabtagene autoleucel to people with mantle cell lymphoma or acute lymphoblastic leukemia. The therapy is normally sold commercially, but this study uses batches that didn't pass commercial quality checks yet are still c…

This early-phase study tests a new treatment called KITE-363 for people with severe autoimmune nerve diseases like multiple sclerosis, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy that have not responded to standard therapies. KITE-363 uses a patient's…

This phase 3 study tests whether a new treatment called KITE-753 works better than the current CAR T-cell therapy, axicabtagene ciloleucel, for adults with large B-cell lymphoma that has come back or not responded after initial treatment. About 550 participants will be randomly a…

This study offers a way for people with large B-cell lymphoma or follicular lymphoma to receive a cell therapy called axicabtagene ciloleucel, even if their specific batch didn't meet commercial quality standards. Participants must have a batch that still passes the company's cli…

This study tests a new treatment called anitocabtagene autoleucel (a type of cell therapy) against standard treatments for people with multiple myeloma that has returned or not responded to 1-3 prior therapies. About 450 participants will be randomly assigned to receive either th…